265 related articles for article (PubMed ID: 32347432)
1. Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer.
Masaki C; Sugino K; Kobayashi S; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Int J Clin Oncol; 2020 Jul; 25(7):1278-1284. PubMed ID: 32347432
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract][Full Text] [Related]
3. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
4. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Evans TRJ; Kudo M; Finn RS; Han KH; Cheng AL; Ikeda M; Kraljevic S; Ren M; Dutcus CE; Piscaglia F; Sung MW
Br J Cancer; 2019 Jul; 121(3):218-221. PubMed ID: 31249394
[TBL] [Abstract][Full Text] [Related]
5. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
6. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the utility of the urine dipstick and urine protein-to-creatinine ratio for predicting microalbuminuria in patients with non-diabetic lifestyle-related diseases -a comparison with diabetes.
Ogi M; Seto T; Wakabayashi Y
BMC Nephrol; 2022 Nov; 23(1):377. PubMed ID: 36434544
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three types of analyzers for urine protein-to-creatinine ratios in dogs.
Ji S; Yang Y; Jeong Y; Hwang SH; Kim MC; Kim Y
J Vet Sci; 2021 Jan; 22(1):e14. PubMed ID: 33522166
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of the quantitative measurement of urine protein at a community-based health checkup: a cross-sectional study.
Naruse M; Mukoyama M; Morinaga J; Miyazaki M; Iseki K; Yamagata K
Clin Exp Nephrol; 2020 Jan; 24(1):45-52. PubMed ID: 31541337
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib-induced renal failure: two first-time case reports and review of literature.
Cavalieri S; Cosmai L; Genderini A; Nebuloni M; Tosoni A; Favales F; Pistillo P; Bergamini C; Bossi P; Licitra L; Locati LD; Alfieri S
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):379-385. PubMed ID: 29617171
[TBL] [Abstract][Full Text] [Related]
13. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
14. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
Hayato S; Shumaker R; Ferry J; Binder T; Dutcus CE; Hussein Z
Cancer Chemother Pharmacol; 2018 Dec; 82(6):971-978. PubMed ID: 30244318
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
16. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Proteinuria Using Urine Protein : Creatine Ratio in Treatment with Molecular Targeted Agents for Advanced Renal Cell Carcinoma.
Nakamura K; Tanaka T; Masumori N; Miyamoto A; Hirano T
Biol Pharm Bull; 2020; 43(10):1506-1510. PubMed ID: 32999160
[TBL] [Abstract][Full Text] [Related]
18. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N; Glen H; Gerrard G; Good J; Lei M; Lyon AR; Strachan M; Wadsley J; Newbold K
Clin Oncol (R Coll Radiol); 2020 May; 32(5):e145-e153. PubMed ID: 31843241
[TBL] [Abstract][Full Text] [Related]
19. Correlation of urine protein/creatinine ratios to 24-h urinary protein for quantitating proteinuria in children.
Huang Y; Yang X; Zhang Y; Yue S; Mei X; Bi L; Zhai W; Ren X; Ding Y; Zhang S; Deng Z; Sun Y
Pediatr Nephrol; 2020 Mar; 35(3):463-468. PubMed ID: 31813022
[TBL] [Abstract][Full Text] [Related]
20. Effect of blood contamination on results of dipstick evaluation and urine protein-to-urine creatinine ratio for urine samples from dogs and cats.
Vientós-Plotts AI; Behrend EN; Welles EG; Chew DJ; Gaillard PR; Busler JN; Lee HP
Am J Vet Res; 2018 May; 79(5):525-531. PubMed ID: 29688781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
